BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Bangladesh approves Sputnik V vaccine

April 28, 2021 | News

The vaccine has been registered under the emergency use authorisation procedure



The Russian Direct Investment Fund (RDIF) announces that the Directorate General of Drug Administration (DGDA) under the Ministry of Health & Family Welfare of the People's Republic of Bangladesh has approved the use of the Russian Sputnik V vaccine against coronavirus.

The vaccine has been registered under the emergency use authorisation procedure (EUA). Bangladesh has become the 62-nd country to authorise the use of Sputnik V. Total population of the countries where Sputnik V is approved for use is 3.2 billion people.

Post-vaccination studies in a number of countries demonstrate that Sputnik V is the safest and most effective vaccine against coronavirus. Sputnik V ranks second among coronavirus vaccines globally in terms of the number of approvals issued by government regulators.

Kirill Dmitriev, CEO, Russian Direct Investment Fund, said, “Bangladesh is one of the most populated countries in Asia and with the help of Sputnik V many lives will be saved in the country. Diversification of the national vaccine portfolio through registration of Sputnik V provides people of Bangladesh with access to one of the best vaccines against coronavirus in the world.”